Literature DB >> 31780234

Extramammary Paget disease of the vulva: Management and prognosis.

Dimitrios Nasioudis1, Madhura Bhadra2, Emily M Ko2.   

Abstract

OBJECTIVE: To evaluate the clinicopathological characteristics, management and prognosis of patients with vulvar extramammary Paget disease of the vulva (EMPD).
MATERIALS AND METHODS: The U.S National Cancer Database was accessed and patients diagnosed between 2004 and 2015 with microscopically confirmed vulvar EMPD were selected. Overall survival (OS) was calculated for patients diagnosed between 2004 and 2014, who had at least one month of follow-up. Five year OS rates were calculated following generation of Kaplan-Meier curves while comparisons were made with the log-rank test.
RESULTS: A total of 2602 patients were identified. Median age at diagnosis was 72 years (range 31-90 years) and the majority were of White race (92%), without any co-morbidities (80.9%). Personal history of another tumor was present in 36.9% of patients. In situ EMPD was diagnosed in 994 cases (38.2%) and the majority (95.1%) were managed with local excision or vulvectomy. Five-year OS was 85.8%, while presence of positive margins was not associated with worse OS (p = 0.38). Invasive EMPD was diagnosed in 1608 (61.8%) patients. Staging information was available for 1172 patients, 75.3% had early stage disease. Most patients underwent surgical treatment (91.6%); 53.6% had positive margins. Performance of lymphadenectomy was infrequent (6.8%). Moreover, immunotherapy (4.5%), chemotherapy (1.5%) and radiation therapy (2.2%) were rarely employed in the management of invasive EMPD. Patients with early stage disease (n = 766) had better OS compared to those with advanced stage (n = 278) (5-yr OS rates were 84.3% and 73.6% respectively, p = 0.015) while presence of positive margins was not associated with worse OS (p = 0.35).
CONCLUSIONS: Extramammary Paget disease is a rare vulvar tumor. Surgical excision is the main treatment option while other modalities are rarely employed. Overall survival rates are encouraging.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Paget; Vulva; Vulvectomy

Mesh:

Year:  2019        PMID: 31780234     DOI: 10.1016/j.ygyno.2019.11.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Current Management and Treatment of Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-04-04

2.  NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target.

Authors:  Maho Murata; Takamichi Ito; Yuka Tanaka; Yumiko Kaku-Ito; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

3.  Prevalence of extramammary Paget's disease in urban China: a population-based study.

Authors:  Shilu Yin; Lu Xu; Shengfeng Wang; Jingnan Feng; Lili Liu; Guozhen Liu; Jinxi Wang; Siyan Zhan; Zhenmin Zhao; Pei Gao
Journal:  Orphanet J Rare Dis       Date:  2021-03-17       Impact factor: 4.123

4.  Mucosal Invasion, but Not Incomplete Excision, Has Negative Impact on Long-Term Survival in Patients With Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Yumiko Kaku-Ito; Masutaka Furue; Takamichi Ito
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

5.  Extramammary Paget disease: five perianal case report and treatment options.

Authors:  Heng Deng; Xiaoli Fang; Ming Li
Journal:  J Surg Case Rep       Date:  2021-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.